Table 3.

Normality test assessment using Shapiro-Wilk (W) statistics and a statistical significance of $p<0.05$ (*) for healthy subjects, idiopathic pulmonary fibrosis (IPF), and coronavirus disease 2019 (COVID-19) patients.

Scale factor ($\tau$)	Healthy subjects		IPF patients		COVID-19 patients
	$\mathrm{W}(26)$	$p$	$\mathrm{W}(26)$	$p$	$\mathrm{W}(51)$	$p$
1	$0.70$	$0.000$*	$0.95$	$0.233$	$0.99$	$0.820$
2	$0.94$	$0.125$	$0.97$	$0.601$	$0.96$	$0.054$
3	$0.80$	$0.000$*	$0.96$	$0.003$*	$0.94$	$0.008$*
4	$0.72$	$0.000$*	$0.85$	$0.001$*	$0.95$	$0.028$*
5	$0.84$	$0.001$*	$0.95$	$0.184$	$0.91$	$0.001$*
6	$0.67$	$0.000$*	$0.83$	$0.001$*	$0.88$	$0.000$*
7	$0.63$	$0.000$*	$0.70$	$0.000$*	$0.79$	$0.000$*
8	$0.79$	$0.000$*	$0.79$	$0.000$*	$0.83$	$0.000$*
9	$0.93$	$0.080$	$0.86$	$0.003$*	$0.84$	$0.000$*
10	$0.92$	$0.048$*	$0.94$	$0.130$	$0.95$	$0.027$*